Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease
Maciej Banach, Vice-Rector for the Collegium Medicum at John Paul II Catholic University of Lublin, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Frontiers in Pharmacology Journal, adding:
“Please see our recent hot topic review on ‘Triglyceride-lowering therapies for hepatic steatosis’ just accepted for the Frontiers in Pharmacology journal with Seyed Saeed Tamehri Zadeh and Peter P. Toth.
Hepatic steatosis, the hallmark of MASLD, is closely associated with elevated plasma and intrahepatic triglyceride (TG) levels, often driven by insulin resistance, atherogenic dyslipidemia, and metabolic syndrome.
Growing evidence suggests that triglyceride-lowering therapies may not only improve systemic lipid profiles but also directly impact hepatic fat accumulation and associated inflammation and fibrosis.
This review explores current and emerging TG-lowering therapies, including fibrates, omega3 fatty acids, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD.
We discuss the mechanistic rationale behind TG-lowering as a therapeutic strategy, summarize key preclinical and clinical trial findings, and evaluate their effects on liver fat content, liver enzymes, fibrosis markers, and histologic outcomes.
While several agents demonstrate promise in reducing intrahepatic fat deposition and improving liver-related outcomes, further large-scale studies are required to establish their long-term efficacy and safety, and potential for disease modification in MASLD/MASH.
Triglyceride-targeted therapies may offer a valuable adjunct or complementary approach to current treatment paradigms focused on weight loss, insulin sensitization, and antagonizing inflammation.
The preprint version is available․”
Title: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives
Author: Seyed Saeed Tamehri Zadeh, Peter Paul Toth, Maciej Banach
Other posts featuring Maciej Banach on Hemostasis Today.
-
Sep 8, 2026, 02:49Jared Rice: High Platelets, Low Clot Risk? – What Makes Neonatal Platelets Different in Sepsis
-
Sep 8, 2026, 02:46Rasha E.: Exploring Polycythemia Vera: Beyond the Hematocrit
-
Sep 8, 2026, 02:35Ahmet Davut Aksu: Plasminogen Supplementation Enhances Alteplase Efficacy in Systemic Embolization Model
-
Sep 7, 2026, 23:56Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month